ADGM · Adagio Medical Holdings, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“As of the report date, we do not believe our existing cash and cash equivalents are sufficient to fund our operating and capital expenditure requirements for at least 12 months from the date of issuance of the audited consolidated financial statements included in this Report. Based on our current research and development plans, we expect to have sufficient resources to fund our planned operations into the fourth quarter of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than expected. No assurance can be given as to whether additional needed financing will be available on terms acceptable to us, if at all. If sufficient funds on acceptable terms are not available when needed, we may be required to suspend or forego certain planned activities. Failure to manage discretionary spending or raise additional financing, as needed, could adversely impact our ability to achieve our intended business objectives and may have an adverse effect on our results of operations and future prospects. These factors raise substantial doubt about our ability to continue as a going concern for the twelve-month period from the date of this filing with the SEC.”View the 10-Q filed Aug 11, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $0 | $0 | — | $300K | |
| — | $684K | — | $1.31M | |
| — | -$684K | — | -$1.01M | |
| — | — | — | -335.33% | |
| $10.2M | $10.64M | — | $15.4M | |
| $9.62M | $10.57M | — | $11.54M | |
| — | $0 | — | — | |
| $839K | $970K | — | $532K | |
| $19.91M | $21.89M | — | $28.24M | |
| -$19.91M | -$21.89M | — | -$27.94M | |
| — | — | — | -9314% | |
| -$19.07M | -$20.92M | — | -$27.41M | |
| $3.11M | $2.91M | — | $1.66M | |
| $390K | $477K | — | $3000 | |
| -$7.23M | -$3.19M | — | -$8.65M | |
| — | -$25.32M | — | -$36.59M | |
| — | $0 | $0 | $0 | |
| -$27.14M | -$25.08M | — | -$36.59M | |
| — | — | — | -12196.67% | |
| -$27.03M | -$25.18M | — | -$36.6M | |
| USD/shares | -$1.36 | -$1.51 | — | -$48.16 |
| USD/shares | -$1.26 | -$1.51 | — | -$48.16 |
| shares | — | 16.58M | — | 759.81K |
| shares | — | 16.58M | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 24,836,000 | 10-Q filed 2026-08-11 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 1,165,000 | 10-Q filed 2026-08-11 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 49 similar-size Medical Devices companies (of 155 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2023 |
|---|---|
| Single Reportable Segment | $300,000 |